Monitor for Cboe Canada approval of the appointment and any subsequent board committee assignments. The addition of a CNS regulatory expert may signal preparation for upcoming FDA interactions for HLP003 Phase 3 data readout.
Price Chart
Executive Summary
Helus Pharma appointed Dr. Suresh Durgam, a former CMO of Intra-Cellular Therapies (acquired by J&J) to its Board of Directors. Dr. Durgam brings deep CNS regulatory and clinical development expertise, having led FDA approvals for CAPLYTA across multiple indications. The appointment is a routine board addition for a clinical-stage biotech and does not include any financial terms or material operational changes.
Key Facts
- Dr. Suresh Durgam appointed to Board of Directors, previously served on Scientific Advisory Board
- Former EVP and CMO of Intra-Cellular Therapies, acquired by Johnson & Johnson in April 2025
- Led FDA approvals for CAPLYTA (lumateperone) for schizophrenia, bipolar depression, MDD
- Appointment subject to approval of Cboe Canada
- No financial terms, compensation, or compensation changes disclosed
Financial Impact
No financial impact disclosed — routine board appointment with no compensation or financial terms disclosed
Risk Factors
- Appointment subject to Cboe Canada approval — delay or denial possible
- No change to pipeline or financial outlook — purely governance
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001833141-26-000091 |
| Document: heluspharmainc-form6xk10x1.htm | 0001833141-26-000091 |
| Document: 0001833141-26-000091-index-headers.html | 0001833141-26-000091 |
| Document: 0001833141-26-000091-index.html | 0001833141-26-000091 |
| Document: 0001833141-26-000091.txt | 0001833141-26-000091 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $10.66 | awaiting T+20 | — | $10.65 (−0.00%) |
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.65 (+5.39%) |
Oct 26, 2026 1d ago | 3 | $10.86 | awaiting T+20 | — | $10.65 (−1.84%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.65 (+1.48%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.65 (+1.48%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.65 (+1.48%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.65 (+1.48%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.65 (+1.48%) |
Oct 15, 2026 12d ago | 6-K | $11.05 | awaiting T+20 | — | $10.65 (−3.57%) |
Oct 15, 2026 12d ago | Press Release | $11.05 | awaiting T+20 | — | $10.65 (−3.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers